medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 5

<< Back Next >>

Ann Hepatol 2018; 17 (5)

Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection

Suzuki M, Minowa K, Tajiri H

Language: English
References: 7
Page: 756-758
PDF size: 156.78 Kb.


ABSTRACT

Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available therapeutic option for selected patients in countries where DAAs have not yet been approved.


REFERENCES

  1. Indolfi G, Thorne C, El Sayed MH, Giaquinto C, Gonzalez-Peralta RP. The challenge of treating children with hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2017; 64: 851-4.

  2. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment- naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 138-47.

  3. Tajiri H, Tanaka Y, Takano T, Suzuki M, Abukawa D, Miyoshi Y, Shimizu T, et al. Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatol Res 2014; 44: E38-44.

  4. Druyts E, Thorlund K, Wu P, Kanters, S, Yaya S, Cooper CL, Mills EJ. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: 961-7.

  5. Jonas MM, Schwarz KB, Gonzalez-Peralta R, Lobritto S, Molleston JP, Murray KF, Rosenthal P, et al. Long-term growth outcomes in children treated for chronic hepatitis C. J Pediatr 2014; 165: 1252-4.

  6. Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, et al. Long-term follow-up of children treated with peginterferon and ribavirin for hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2017; 64: 89-94.

  7. Tahata Y, Hiramatsu N, Oze T, Morishita N, Harada, N, Yamada R, Yakushijin T, et al. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin. J Gastroenterol 2016; 51: 252-9.




2020     |     www.medigraphic.com